Capacity building and predictors of success for HIV‐1 drug resistance testing in the Asia‐Pacific region and Africa

• DOI: 10.7448/ias.16.1.18580
• Publication Date: 2013-07-10T11:53:42Z
• Authors: Sally Land; Julian Zhou; Philip Cunningham; Annette H Sohn; Thida Singtoroj; David Katzenstein; Marita Mann; David Sayer; Rami Kantor
• Keywords: HIV drug resistance; Electropherogram

The TREAT Asia Quality Assessment Scheme (TAQAS) was developed as a quality assessment programme through expert education and training, for laboratories in the Asia-Pacific Africa that perform HIV drug-resistance (HIVDR) genotyping. We evaluated performance factors associated with high-quality HIVDR Laboratories used their standard protocols to test panels of human immunodeficiency virus (HIV)-positive plasma samples or electropherograms. Protocols were documented according newly scoring system, agreement panel-specific consensus sequence, detection mutations (DRMs) mixtures wild-type resistant (mixtures). High-quality defined ≥95% DRMs. Over 4.5 years, 23 participating 13 countries tested 45 (30 HIV-1 subtype B; 15 non-B subtypes) nine panels. Median DRMs 88-98% 90-97% electropherogram supported amend improve outcomes appropriate. Three detected <80% early demonstrated subsequent improvement. Sample complexity - number (p<0.001) (p<0.001); laboratory sequence (p<0.001), high performance; sample format (plasma electropherogram), genotyping protocol not. achieved TAQAS collaborative network. quality. conducting are encouraged participate programmes.